RTW INVESTMENTS, LP - ACHILLION PHARMACEUTICALS IN ownership

ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 2 filers reported holding ACHILLION PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
RTW INVESTMENTS, LP ownership history of ACHILLION PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2019$44,076,000
-11.7%
7,309,383
-47.3%
1.66%
-44.0%
Q3 2019$49,912,000
+34.3%
13,864,3830.0%2.97%
+49.5%
Q2 2019$37,157,000
-8.7%
13,864,383
+0.8%
1.98%
-28.5%
Q1 2019$40,698,000
+86.2%
13,749,3830.0%2.78%
+36.5%
Q4 2018$21,862,000
-56.3%
13,749,383
+1.1%
2.04%
-32.1%
Q3 2018$50,032,000
+30.6%
13,595,704
+0.4%
3.00%
+8.4%
Q2 2018$38,324,000
-23.5%
13,541,997
+0.3%
2.76%
-42.0%
Q1 2018$50,074,000
+28.3%
13,496,902
-0.4%
4.76%
-26.8%
Q4 2017$39,015,000
+10.8%
13,546,902
+72.8%
6.51%
+6.2%
Q3 2017$35,201,000
+382.2%
7,839,766
+392.9%
6.13%
+298.3%
Q2 2017$7,300,000
+517.6%
1,590,454
+455.5%
1.54%
+245.8%
Q4 2016$1,182,000
-93.4%
286,285
-87.0%
0.44%
-91.8%
Q3 2016$17,891,000
-5.4%
2,208,749
-8.9%
5.41%
-16.3%
Q2 2016$18,908,000
-4.3%
2,424,136
-5.3%
6.46%
-9.9%
Q1 2016$19,754,000
-7.9%
2,558,859
+28.7%
7.17%
+1.2%
Q4 2015$21,460,000
+19.9%
1,988,914
-23.2%
7.09%
+27.5%
Q3 2015$17,896,000
-19.7%
2,589,818
+3.0%
5.56%
-14.3%
Q2 2015$22,287,000
+39.3%
2,515,433
+55.0%
6.49%
-10.2%
Q1 2015$15,999,000
-19.5%
1,622,6330.0%7.22%
-1.8%
Q4 2014$19,877,0001,622,6337.35%
Other shareholders
ACHILLION PHARMACEUTICALS IN shareholders Q1 2020
NameSharesValueWeighting ↓
RA Capital Management 12,033,220$92,896,00011.87%
RTW INVESTMENTS, LP 2,558,859$19,754,0007.17%
TURNER INVESTMENTS LLC 859,560$6,636,0001.80%
DAFNA Capital Management LLC 236,500$1,826,0001.58%
Ghost Tree Capital, LLC 250,000$1,930,0001.09%
Orbimed Advisors 11,519,700$88,932,0000.94%
Rock Springs Capital Management LP 1,220,000$9,418,0000.79%
Opus Point Partners Management, LLC 99,000$764,0000.59%
Bellevue Group AG 420,000$3,242,0000.59%
Cormorant Asset Management, LP 500,000$3,860,0000.58%
View complete list of ACHILLION PHARMACEUTICALS IN shareholders